Lifotronic(SH:688389)2023-10-24 16:00Financial Performance - In the first three quarters of 2023, the company achieved total operating revenue of 809 million RMB, a year-on-year increase of 20.15%[15] - The net profit attributable to shareholders of the parent company for the same period was 205 million RMB, representing a year-on-year growth of 33.87%[15] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was 188 million RMB, up 31.09% year-on-year[15] - The company's operating revenue for the third quarter reached ¥250,692,446.01, representing a year-on-year increase of 10.64%[29] - The net profit attributable to shareholders for the third quarter was ¥70,396,795.60, reflecting a year-on-year growth of 31.42%[29] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥62,078,800.40, up 23.36% year-on-year[29] - The net profit for the third quarter of 2023 was CNY 204,276,689.13, an increase of 33.5% compared to CNY 152,955,946.85 in the same period of 2022[63] - The operating profit for the third quarter was CNY 220,163,292.77, up from CNY 161,986,079.65, reflecting a growth of 35.8% year-over-year[63] - The company reported a total comprehensive income of CNY 204,276,689.13 for the quarter, compared to CNY 152,955,946.85 in the previous year, marking a growth of 33.5%[63] Research and Development - The company obtained 17 patents during the reporting period, including 6 invention patents and 5 software copyrights[16] - The company is focusing on the in vitro diagnostic field, enhancing its comprehensive competitiveness through continuous R&D investments[16] - The company has certified a fully automated biochemical analyzer that can be cascaded with a high-throughput electrochemiluminescence immunoassay analyzer, improving industry competitiveness[17] - The company is investing in laboratory automation to provide more convenient solutions for hospital laboratories and medical testing centers[17] - The company's products in the clinical testing HPLC product line continue to achieve rapid growth, offering various functional combinations and testing speeds[18] - The company's R&D investment for the third quarter was ¥41,328,429.53, accounting for 16.49% of operating revenue, a decrease of 4.40 percentage points year-on-year[37] - Research and development expenses for the first three quarters of 2023 amounted to ¥138,706,304.11, slightly down from ¥139,218,794.69 in the previous year[57] Product Development and Launches - The company launched new products, including a fully automated red blood cell osmotic fragility analyzer, which has begun market promotion[20] - The company has submitted a registration application for the strong pulse therapy device and successfully developed core components for the Q-switch laser therapy device[21] - The ultrasound therapy device was certified in March and launched in June, quickly becoming a top seller in its category[21] - The company plans to launch a new intermittent air wave therapy device in 2024 to meet VTE prevention needs for bedridden patients[21] Assets and Liabilities - The total assets of the company as of September 30, 2023, amounted to ¥2,114,645,478.38, a 16.16% increase compared to the end of the previous year[37] - Total assets as of September 30, 2023, reached ¥2,114,645,478.38, compared to ¥1,820,510,028.30 at the end of 2022, marking an increase of 16.16%[56] - Total liabilities as of September 30, 2023, were ¥475,990,841.82, up from ¥377,016,430.64 at the end of 2022, reflecting a growth of 26.19%[55] - The company's total equity as of September 30, 2023, was ¥1,638,654,636.56, compared to ¥1,443,493,597.66 at the end of 2022, representing an increase of 13.54%[57] - The company's total liabilities rose to ¥990,378,414.64, compared to ¥507,569,655.81 in the previous year, representing an increase of 95%[78] Cash Flow and Financial Position - Cash and cash equivalents as of September 30, 2023, were ¥1,110,843,081.23, an increase of 19.26% from ¥931,641,103.41 at the end of 2022[48] - Accounts receivable increased to ¥129,617,435.26 as of September 30, 2023, compared to ¥95,118,794.61 at the end of 2022, representing a growth of 36.25%[48] - Inventory as of September 30, 2023, was ¥183,230,250.43, up from ¥142,431,926.91 at the end of 2022, indicating a rise of 28.63%[51] - Cash flow from operating activities generated a net amount of CNY 123,684,087.50, compared to CNY 108,548,182.62 in the previous year, indicating a 13.3% increase[67] - The company's cash inflow from operating activities totaled ¥1,026,581,360.29, up from ¥882,730,464.50, reflecting a growth of 16.3%[84] - The company raised CNY 321,289,366.66 from financing activities, significantly higher than CNY 177,940,416.67 in the same period last year[69] - The company experienced a foreign exchange gain of CNY 9,686,714.43 during the quarter, compared to a gain of CNY 24,539,296.14 in the previous year[69] Strategic Partnerships and Collaborations - The company has been recognized as a strategic partner of Dalian Medical University for the Smart Testing Industry College, enhancing collaboration in medical technology innovation[23] - The company has a remaining balance of ¥2,103,767.98 from raised funds, with ongoing projects nearing completion[26] Accounting and Reporting Changes - The company has adopted new accounting standards starting in 2023, which may affect financial reporting[85]